ISPY2
I-SPY 2 Breast Dynamic Contrast Enhanced MRI Trial (ISPY2)
Serial breast DCE-MRI and T2-weighted MRI of 719 women with locally advanced breast cancer in the I-SPY 2 neoadjuvant chemotherapy trial, with SER and enhancement maps, functional tumor volume masks and pathologic response.
Overview
ISPY2 is the TCIA image collection of the I-SPY 2 TRIAL (NCT01042379), a multi-center adaptive trial that tests new drugs for high-risk, locally advanced breast cancer given before surgery as neoadjuvant chemotherapy. The trial uses the change in tumor volume on dynamic contrast-enhanced (DCE) MRI during treatment to steer randomization. The collection covers patients randomized between 2010 and 2016 and was released in May 2022 under CC BY 4.0.
Composition
The collection holds 719 women aged 24 to 73 (mean 48.9 years) with 2,688 MRI studies, 32,411 DICOM series and about 5.6 million images. Each patient had up to four exams: before treatment (T0), after three weeks of paclitaxel-based therapy (T1), between the paclitaxel and anthracycline regimens (T2) and before surgery (T3). Counted from the open metadata digest, 717 patients have a T0 study, 690 a T1, 647 a T2 and 634 a T3.
These 719 patients are one part of "I-SPY2 Imaging Cohort 1". The other 266 patients of that cohort are published as the separate TCIA collection ACRIN-6698 (ACRIN 6698/I-SPY2 Breast DWI). The collection page provides a combined manifest for all 985 patients and warns that results from the 719 alone are not comparable to published trial results. A clinical spreadsheet for the 985 patients carries pathologic outcome and receptor status, and a separate sheet gives four MRI features for a 384-patient subset.
Acquisition
More than 22 sites scanned patients prone on 1.5 T or 3 T systems with a dedicated breast coil, following a shared protocol. Each patient stayed on the same scanner configuration for all visits. The collection includes axial bilateral T2-weighted series and T1-weighted DCE series. DWI was acquired but is not included. Per the metadata digest, most patients were scanned on GE systems, followed by Siemens and Philips.
Annotations
Each DCE study comes with derived objects from the trial's analysis: an ipsilateral cropped DCE series, early and late percent enhancement maps, a signal enhancement ratio (SER) map, and a functional tumor volume (FTV) analysis mask stored as DICOM SEG. The mask encodes thresholds and manually drawn volume-of-interest and exclusion regions.
Known limitations
- The T2-weighted series are not curated.
- Some derived objects are not strictly DICOM compliant.
- FTV values stored in the derived objects can differ slightly from the values used in the trial analysis.
- DWI is missing from this collection.
Cohort
Aggregate numbers from the sources below. Bars are relative to the 719 subjects.
Sex
- Female 719 100%
Age
mean 48.9± 11 · range 24 to 73No age bins reported.
Condition
subjects, values can overlap
- Breast cancer 719 100%
Anatomy
subjects
- Breast 719 100%
Scanner vendor
subjects
- GE HealthCare 426 59%
- Siemens Healthineers 210 29%
- Philips 83 12%
License and access
Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer
Download without an account
DICOM images are downloaded with the TCIA Data Retriever from a manifest file. No account is needed. A second manifest on the same page downloads the full I-SPY2 Imaging Cohort 1 (985 patients), which adds the 266 patients of the separate ACRIN-6698 collection. The clinical spreadsheet for all 985 patients is an open XLSX download.
Creative Commons Attribution 4.0 International
Use, share and adapt the data for any purpose, including commercial use, as long as you credit the creators.
What you can do
- Yes
- Yes
- Yes
- Yes
What you can share
- Yes
- Yes
- Yes
What you must do
- Yes
- Share alike No
- No
- No
- Manuscript review No
- Release code No
- Return results No
- Delete after use No
Limits
- No
- Location limits No
Citation
Li, W., Newitt, D. C., Gibbs, J., Wilmes, L. J., Jones, E. F., Arasu, V. A., Strand, F., Onishi, N., Nguyen, A. A.-T., Kornak, J., Joe, B. N., Price, E. R., Ojeda-Fournier, H., Eghtedari, M., Zamora, K. W., Woodard, S. A., Umphrey, H., Bernreuter, W., Nelson, M., ... Hylton, N. M. (2022). I-SPY 2 Breast Dynamic Contrast Enhanced MRI Trial (ISPY2) (Version 1) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/TCIA.D8Z0-9T85
All numbers
Every number on this page, as stored in stats.csv, with its source.
| Measure | Breakdown | Value | Source |
|---|---|---|---|
| Subjects | total | 719 | tcia-ispy2 Summary table |
| Studies | total 719-patient image download | 2,688 | tcia-ispy2 Data Access (Version 1) |
| Scans | total DICOM series, original and derived (maps and SEG masks) | 32,411 | tcia-ispy2 Data Access (Version 1) |
| Images | total DICOM images | 5,586,493 | tcia-ispy2 Data Access (Version 1) |
| Subjects | sex=female | 719 | tcia-ispy2 Demographic Summary of Available Imaging |
| Mean age | total | 48.9 | tcia-ispy2 Demographic Summary of Available Imaging |
| Age SD | total | 11 | tcia-ispy2 Demographic Summary of Available Imaging |
| Median age | total | 49 | tcia-ispy2 Demographic Summary of Available Imaging |
| Minimum age | total | 24 | tcia-ispy2 Demographic Summary of Available Imaging |
| Maximum age | total | 73 | tcia-ispy2 Demographic Summary of Available Imaging |
| Subjects | condition=breast_cancer | 719 | tcia-ispy2 Summary table |
| Subjects | anatomy=breast | 719 | tcia-ispy2 Summary table |
| Subjects | vendor=ge recorded as GE MEDICAL SYSTEMS | 426 | tcia-ispy2-digest Patient ID, Manufacturer columns |
| Subjects | vendor=siemens recorded as SIEMENS | 210 | tcia-ispy2-digest Patient ID, Manufacturer columns |
| Subjects | vendor=philips recorded as Philips Medical Systems or Philips Healthcare; 3 further subjects have series with Manufacturer 0000000 | 83 | tcia-ispy2-digest Patient ID, Manufacturer columns |
Sources
The keys used in the table above.